The Clinical Details of MYH9-Related Disease and DFNA17 in a Large Japanese Hearing Loss Cohort
Authors:
- Shinichi GotoSGShinichi Goto
- Akira SasakiASAkira Sasaki
- Shin-Ya NishioShin-Ya Nishio
- Chikako ShinkawaCSChikako Shinkawa
- Kiyoshi OdaKOKiyoshi Oda
- Tetsuro WadaTWTetsuro Wada
- Kotaro IshikawaKIKotaro Ishikawa
- Tetsuo IkezonoTITetsuo Ikezono
- Shin-Ichiro OkaSOShin-Ichiro Oka
- Nobuhiro NishiyamaNNNobuhiro Nishiyama
- Taku ItoTITaku Ito
- Marina KobayshiMKMarina Kobayshi
Open Access
Abstract
Background/Objectives: MYH9 gene variants cause MYH9-related disease (MYH9-RD), which is also known as Epstein syndrome, Fechtner syndrome, May–Hegglin anomaly, and Sebastian syndrome. MYH9-RD is characterized by sensorineural hearing loss, macrothrombocytopenia, thrombocytopenia, hematuria/proteinuria, glomerulonephritis, cataracts purpura, and mucosal bleeding. In addition, the MYH9 gene is also known to be causative of autosomal dominant non-syndromic hearing loss (DFNA17). MYH9-RD is a relatively rare disorder, and the detailed clinical features and mutational spectra remain unclear. Methods: In this study, we performed next-generation sequencing analysis for 15,684 hearing loss patients and identified MYH9-associated hearing loss patients. Detailed clinical information was collected for these patients and summarized. Results: In this study, we identified 24 patients from 18 families with MYH9-associated hearing loss. We clarified the details of hearing deterioration observed in patients based on collected serial audiogram data. Some cases showed rapid hearing deterioration that worsened by about 50 dB within 5 years. Hearing loss is more likely to progress in patients with myosin head domain variants than in patients with myosin tail domain variants, but hearing loss in each set of patients finally deteriorates to bilateral profound hearing loss. Conclusions: In this study, we were able to clarify the detailed characteristics of MYH9-RD- and DFNA17-related hearing loss in a relatively large number of patients, particularly in some cases that showed rapid and asymmetrical hearing deterioration progressing to bilateral profound hearing loss. Our data will be useful for providing more appropriate treatment and follow-up for MYH9-associated hearing loss.Keywords
This publication has 39 references indexed in Scilit:
- The genetic etiology of hearing loss in Japan revealed by the social health insurance-based genetic testing of 10K patientsHuman Genetics, 2021
- Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing lossHuman Mutation, 2018
- The Clinical Next-Generation Sequencing Database: A Tool for the Unified Management of Clinical Information and Genetic Variants to Accelerate Variant Pathogenicity ClassificationHuman Mutation, 2017
- Comprehensive genetic testing in the clinical evaluation of 1119 patients with hearing lossHuman Genetics, 2016
- Mutation spectrum and genotype‐phenotype correlations in a large French cohort of MYH9‐Related DisordersMolecular Genetics & Genomic Medicine, 2014
- MYH9-Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype-Phenotype CorrelationsHuman Mutation, 2013
- A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous DiseasesHuman Mutation, 2013
- A new feature of the MYH9-related syndrome: Chronic transaminase elevationHepatology, 2012
- Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history ofMYH9-related diseaseHuman Mutation, 2007
- Identification of six novel MYH9 mutations and genotype–phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusionsJournal of Human Genetics, 2001